UK markets open in 1 minute

Novozymes A/S (NVZMF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
47.12-3.48 (-6.88%)
At close: 01:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close50.60
Open48.68
BidN/A x N/A
AskN/A x N/A
Day's range47.12 - 49.00
52-week range38.16 - 82.30
Volume5,395
Avg. volume1,452
Market cap12.778B
Beta (5Y monthly)0.35
PE ratio (TTM)32.05
EPS (TTM)1.47
Earnings dateN/A
Forward dividend & yield0.82 (1.61%)
Ex-dividend date17 Mar 2022
1y target estN/A
  • Globe Newswire

    Novozymes delivers strong half year results and narrows full-year outlook upwards

    Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%. COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good mome

  • Globe Newswire

    Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

    Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented. COPENHAGEN, Denmark – 15 July 2022. Novozymes has been able to partially shield its customers from a large part of the global challenges, securing business continuity and high price stability relative to other suppliers. However, Novozymes will further substantially increase prices at a level at least in line with the current

  • Zacks

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?